Skip to Content

'
Monica E. Loghin, M. D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Residency Program Director, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. Loghin is an Assistant Professor of Neuro-Oncology at M. D. Anderson Cancer Center.  She completed her neurology residency training at University of Texas Health Science Center and thereafter she was accepted and completed a Neuro-Oncology fellowship at MD Anderson Cancer Center.  Dr. Loghin is involved in patient clinical care as well as in the training program for Neuro-Oncology fellows and neurology residents. She currently serves as the Department of Neuro-Oncology Residency Program Director, dedicating a lot of effort and energy in developing a competitive and high quality teaching program.

Research Interests

Dr. Loghin's research interests are focused on neurological complications related to cancer treatment, particularly neurological and cognitive deficits induced by radiation therapy. She is collaborating closely with the Neuropschylogy Section in developing new therapeutic strategies  for cancer related cognitive dysfunction.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 431
Houston, TX 77030
Phone: 713-745-4098
Fax: 713-794-4999
Email: mloghin@mdanderson.org

Education & Training

Degree-Granting Education

1983 "Gr.T. Popa" University of Medicine and Pharmacy, Iasi, Romania, MD, Medicine

Postgraduate Training

12/2003-11/2005 Clinical Fellowship, Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Vinay Puduvalli
12/2000-11/2003 Clinical Residency, Neurology, UT Health Science Center, Houston, TX, Dr. Maya Schiess
12/1999-11/2000 Clinical Residency, Internal Medicine, UT Health Science Center, Houston, TX, Dr. Mark Farnie

Board Certifications

2005 The American Board of Psychiatry & Neurology
1992 The Romanian Board of Neurology

Experience/Service

Academic Appointments

Associate Professor, Department of Neurology, The University of Texas Medical Branch, Galveston, TX, 4/2010-present
Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2006-8/2012

Honors and Awards

2012 Nominated for Gerald P. Bodey Award for Excellence in Education, University of Texas MD Anderson Cancer Center

Selected Publications

Peer-Reviewed Original Research Articles

1. Loghin ME, Groves M, Garciarena P,. Glioblastoma: Molecular biology and its impact on personalized treatment. Expert Review of Neurotherapeutics. In Press.
2. Penas-Prado M, Woo S, Lagrone L, Fisch MJ, Groves MD, degroot JF, Puduvalli V, Colman H, Conrad CA, Loghin ME, Hsu SH, Gonzalez J, Mahajan A, Yung WKA, Chang E, ; Levin VA, Volas-Redd G, Giglio P, Salacz, ME, Floyd JD, Aldape KD. Randomized Phase II Adjuvant Factorial Study of Dose-dense Temozolomide Alone and in Combination with Isotretinoin, Celecoxib, and/or Thalidomide for Glioblastoma. Neuro-Oncology. In Press.
3. Abouharb S, Ensor J, Loghin ME, Katz R, Moulder SL, Esteva FJ, Smith B, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: The importance of tumor subtype. Breast Cancer Res Treat. e-Pub 7/2014. PMID: 25038877.
4. Le EM, Loghin ME. Posterior reversible encephalopathy syndrome: A neurologic phenomenon in cancer patients. Curr Oncol Rep 16(5):383-392, 5/2014. PMID: 24595679.
5. Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer 118(14):3599-606, 7/2012. e-Pub 11/2011. PMID: 22086614.
6. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, Prabhu S, Loghin M, Gilbert MR, Jackson EF. Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System. Int J Radiat Oncol Biol Phys 79(5):1487-95, 4/2011. e-Pub 4/2010. PMCID: PMC2908725.
7. Loghin M, Prados M, Wen P, Junck L, Lieberman F, Fine H, Fink K, Mehta M, Kuhn J, Lamborn K, Chang S, Cloughesy T, DeAngelis L, Robins HI, Aldape K, Yung, WKA. Phase I study of Temozolomide and Irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. Clin Cancer Res 13(23):7133-7138, 12/2007. PMID: 18056194.
8. Radu A, Alecu CS, Raclariu A, Nanu L, Loghin M, Stanciu E, Necula A, Ionescu-Tirgoviste C, Patrugan V. CompAc information system for traditional Chinese medicine. Stud Health Technol Inform 81:401-3, 2001. PMID: 11317777.
9. Loghin M, Prodan R, Stefanache F. The role of evoked potentials in the diagnosis of posterior fossa tumors. Acta Neurologica Moldavica, 1994.
10. Pendefunda G, Prodan R, Loghin M. Cerebral hemorrhage in blood disorders. Journal of the Society of Physicians and Nature Scientists, 1989.

Invited Articles

1. Vaillant B, Loghin M. Treatment of spinal cord tumors. Curr Treat Options Neurol 11(4):315-24, 7/2009. e-Pub 6/2009. PMID: 19523357.
2. Penas-Prado M, Loghin M. Spinal cord compression in cancer patients: Review of diagnosis and treatment. Curr Oncol Rep 10(1):78-85, 1/2008. PMID: 18366964.
3. Loghin M, Levin VA. Headache related to brain tumors. Curr Treat Options Neurol 8(1):21-32, 1/2006. PMID: 16343358.
4. Gilbert MR, Loghin M. The Treatment of Malignant Gliomas. Curr Treat Options Neurol 7(4):293-303, 7/2005. PMID: 15967092.

Abstracts

1. Loghin M, Melhem-Bertrandt A, Penas-Prado M, Zaidi T, Katz R. HER2 targeted therapies and leptomeningeal disease. Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, (SNO), 2013, San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii119 (#NO-085), 11/2013.
2. Conrad C, Yung WKA, deGroot J, Gilbert M,Loghin M, Penas-Prado M, Tremont I, Silberman S, Picker D. Phase 1 trial of bevacizumab plus TPI 287 in adults with recurrent glioblastoma (GBM). Neuro-Oncology. In: Proceedings from the 18th Annual Meeting of the Scientific Meeting and Education Day of the Society for Neuro-Oncology, 2013, (SNO) San Francisco, CA, November 21 – 24, 2013 15(supplement 3):iii106 (#NO-085), 11/2013.
3. Raizer JJ, Giglio P, Hu JL, Groves MD, Merrell R, Conrad CA, Phuphanich S, Puduvalli VK, Loghin ME, Paleologos N, Yung WKA, Vaillant BD, Rudnick JD, Chamberlain MC, Vick N, Grimm SA, Tremont-Lukats I, DeGroot JF, Aldape KD, Gilbert MR. BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GMB) without MGMT promoter methylation. J Clin Oncol 31, 2013 (suppl; abstr 2019). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31 (#2051), 6/2013.
4. Abouharb S, Ensor J, Loghin ME, Katz R, Gonzalez-Angulo AM, Esteva FJ, Moulder SL, Valero V, Hortobagyi GN, Melhem-Bertrandt A. Leptomeningeal disease and breast cancer: Relationship of outcome and subtype. J Clin Oncol 31, 2013 (suppl; abstr 601 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31 (#601), 6/2013.
5. Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, de groot, JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess, KR, Aldape KD, Gilbert MR, Yung, WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma. J Clin Oncol 31, 2013 (suppl; abstr TPS2106 ). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31 (#TPS2106), 6/2013.
6. Case, D, Naughton MJ, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk SC, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG, Rapp SR. Quality of life (QOL) and cognitive status among irradiated brain tumor survivors treated with donepezil or placebo. J Clin Oncol 31, 2013 (suppl; abstr 2051). In proceedings: Annual Meeting of the American Society of Clinical Oncology (ASCO), 2013, May 31, - June 4, 2013, Chicago, IL 31 (#2051), 6/2013.
7. Zohrevand P, Loghin M. Transient Leukoencephalopathy after Intrathecal Chemotherapy Mimicking Stroke. Neurology. In Proceedings: American Academy of Neurology (AAN) meeting, New Orleans LA 4/24-4/27/2012 78 (#PO6.015), 4/2012.
8. Colman H, Gilbert M, Yung WKA, Aldape K, deGroot J, Conrad C, Levin V, Groves M, Loghin M, Pelloski C, Puduvalli V. A phase I study of Sorafen1B with radiation and temozolomide in newly diagnosed glioblastoma. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplemement 3):iii61 (#NO-89), 11/2011.
9. Groves MD, DeGroot J, Loghin M, Conrad C, Hess K, Ictech S, Hunter K, Yung WKA. A phase I study of Temozolomide and Intrathecal Liposomal Cytarabine in patients with neuroplastic meningitis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii43 (#NO-11), 11/2011.
10. Hamilton JD, Levin VA, Hou P, Prabhu S, Loghin ME, Gilbert MR, Bassett RL, Wang J. Advanced MR imaging shows decreased vessel leakiness/edema and may predict complications in Bevacizumab therapy of brain radiation necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii142 (#RA-28), 11/2011.
11. Hamilton JD, Wang J, Levin VA, Hou P, Loghin ME, Gilbert MR, Leeds NE, deGroot, JF, Puduvalli V, Jackson EF, Yung WKA, Kumar AJ. Normalized baseline ADC values predict problems associated with Bevacizumab treatment for glioblastoma multiforme or brain radiation induced necrosis. Neuro-Oncology. Proceedings In: 16th Annual Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17 - November 20, 2011 13(Supplement 3):iii137 (#RA04), 11/2011.
12. Paker AM, Chi L, Kamiya-Matsuoka C, Loghin ME. Posterior reversible encephalopathy syndrome in cancer patients. Neurology. In Proceedings: 16 Annual Scientific Meeting of the Society for Neuro-Oncology, Orange County, CA, November 17-20, 2011 78 (#PO6.015), 11/2011.
13. Paker AM, Chi L, Ruiz MD, Loghin ME. Posterior reversible encephalopathy syndrome in patients with cancer. J Clin Oncol 29: 2011 (suppl; abstr 2561). In Proceedings: 2011 Annual American Society of Clinical Oncology (ASCO), Chicago IL, June 4-7, 2011 29 (#2561), 6/2011.
14. Puduvalli VK, Penas-Prado M, Gilbert MR, Groves MD, Hess KR, Levin VA, de Groot J, Colman H, Conrad CA, Loghin ME, Hunter K, Yung WKA. Phase I study of Vorinostat combined with Isotretinoin and Carboplatin in Adults with Recurrent Malignant Gliomas. Neuro-Oncology: In proceedings of the 2010 Annual Meeting of the Society for Neuro-Oncology (SNO), Montreal, Canada, November 18 - November 21, 2010 (#OT-02), 11/2010.
15. Loghin M, Groves M. Neoplastic meningitis in unknown primary neoplasms. Journal of Clinical Oncology. In: 2006 ASCO Annual Meeting Proceedings, 2006, Atlanta Georgia 24(18-S) (#11517), 6/2006.

Grant & Contract Support

Title: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 4/1/2007 - 3/31/2011

Last updated: 7/24/2014